Page 239«..1020..238239240241..250260..»

Molecular Biology with an Industrial Placement Year BSc – India Education Diary

Posted: September 8, 2022 at 2:09 am

The University of Sheffield, UK is inviting applications for its Molecular Biology with an Industrial Placement Year BSc course starting in September 2023.

Discover the diverse range of biochemical, genetic and microbiological approaches needed to understand life at a molecular level. Youll have the opportunity to do a year-long, paid work placement as part of your degree.

University of Sheffields students have found placements at global pharmaceutical companies such as GSK and Pfizer, but your placement doesnt have to be in the lab. You could apply your scientific knowledge and transferable skills outside of the bioscience industry in areas including market research, communications or business development.

A placement is a great opportunity to test out a career path and many students are offered a graduate-level job at the end. Youll pay reduced fees for the year youre on placement and youll still have the support you need from your tutor and the University.

During your time at Sheffield youll study the methods scientists use to sequence genomes, clone and engineer genes, determine molecular structures and analyse cell growth in humans, plants and microbes. Well also show you how this knowledge enables us to develop novel biotechnological solutions to global challenges such as sustainable production and combating disease.

From your first year youll study modules that span the molecular biosciences covering molecular biology, biochemistry, genetics and microbiology. Alongside these modules youll have the freedom to explore complementary topics across the breadth of bioscience, such as biomedicine, ecology, plant science and zoology. This flexibility allows you to study molecular biology in greater depth, keep your interests broad or even switch to another biosciences degree. No matter what modules you choose to study, youll develop the practical laboratory and transferable skills that make our graduates attractive to employers including project management, problem solving, communication skills and data analysis.

You will get plenty of opportunities to apply your new skills and knowledge too. Youll be in the lab completing in-depth practicals across molecular genetics, DNA manipulation and protein structure analysis, and youll get the chance to use cutting-edge equipment to run your own in-depth research projects in an area such as clinical diagnostics or brewing biotechnology.

Duration 4 years

Eligibility-80% in Standard XII including Biology and a second science. IELTS grade of 6.5 with a minimum of 6.0 in each component; or an alternative acceptable English language qualification.

Fee Tuition fees for 2023 entry have not been confirmed. Please use overseas 2022 annual tuition fee 25,670 as a guide.

For further information https://www.sheffield.ac.uk/undergraduate/courses/2023/molecular-biology-industrial-placement-year-bsc or contact : biosciences-ug@sheffield.ac.uk

Excerpt from:
Molecular Biology with an Industrial Placement Year BSc - India Education Diary

Posted in Molecular Genetics | Comments Off on Molecular Biology with an Industrial Placement Year BSc – India Education Diary

Whole Exome Sequencing Market Projected to Reach CAGR of 19.0% Forecast by 2029, Global Trends, Size, Share, Growth, Future Scope and Key Player…

Posted: September 8, 2022 at 2:09 am

CHICAGO, Sept. 07, 2022 (GLOBE NEWSWIRE) -- A Qualitative Research Study accomplished by Data Bridge Market research's database of 350 pages, titled as "Global Whole Exome Sequencing Market" with 100+ market data Tables, Pie Charts, Graphs & Figures spread through Pages and easy to understand detailed analysis. This Whole Exome Sequencing report contains a comprehensive data of market definition, classifications, applications, engagements, market drivers and market restraints of this industry all of which is derived from Porte's Five Forces analysis. Market definition covered in this Whole Exome Sequencing report gives the scope of particular product with respect to the driving factors and restraints in the market. The sources of data and information mentioned in the Whole Exome Sequencing report are very reliable and include websites, annual reports of the companies, journals, and mergers which are checked and validated by the market experts.

Global whole exome sequencing market is expected to gain market growth in the forecast period of 2022 to 2029. Data Bridge Market Research analyses that the market is growing with a CAGR of 19.0% in the forecast period of 2022 to 2029. The increase in healthcare expenditure and funding are the major drivers which propelled the demand of the market in the forecast period.

Get Sample Report in PDF Version along with Graphs and Figures @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-whole-exome-sequencing-market

MarketSynopsis:-

Whole exome is a genomic technique for sequencing the entire protein-coding region of genes in a genome. Whole exome sequencing is available to patients who are searching for a unifying diagnosis for multiple medical conditions. A laboratory process that is used to determine the nucleotide sequence primarily of the exonic (or protein-coding) regions of an individuals genome and related sequences, representing approximately 1% of the complete DNA sequence, also called WES. Whole-exome sequencing is a widely used whole exome sequencing method that involves sequencing the protein-coding regions of the genome. The human exome represents less than 2% of the genome, but contains ~85% of known disease-related variants, making this method a cost-effective alternative to whole-genome sequencing.

Exome sequencing using exome enrichment can efficiently detect coding variants across a wide range of applications, including population genetics, genetic disease and cancer studies. The growth of the global whole exome sequencing market is attributed to the reduction in time and cost for sequencing. With the development of new technologies and cancer cure treatment, the whole exome sequencing market in clinical oncology has huge potential in the coming years.

The major companies which are dealing in the whole exome sequencing market are

Access Full 350 Pages PDF Research Report @ https://www.databridgemarketresearch.com/checkout/buy/enterprise/global-whole-exome-sequencing-market

Recent Development

Opportunity

The demand for whole exome sequencing is increasing in the market owing to the increased incidence of geneticdisease along with increased geriatric population across the region. Thus, the top market players have implemented the strategy of collaboration with other market players aimed at improving business operations and profitability.

Global Whole Exome Sequencing Market Segmentation

Global Whole Exome Sequencing Market is segmented on the basis of component, product and service, application, end user and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Component

Product and Services

Application

End User

Distribution Channel

Browse In-depth Report Along with Facts and Figures @ https://www.databridgemarketresearch.com/reports/global-whole-exome-sequencing-market

Regional Analysis/insights

The whole exome sequencing market is analyzed and market size information is provided by component, product and service, application, end user and distribution channel.

The countries covered in the whole exome sequencing market report are U.S., Canada, Mexico, Germany, France, Italy, U.K., Spain, Netherlands, Russia, Switzerland, Turkey, Belgium, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, Saudi Arabia, South Africa, UAE, Israel, Egypt and Rest of Middle East & Africa.

North America is dominating due to the presence of key market players along the largest consumer market with high GDP. U.S. is expected to grow due to rise in technological advancement.

Key Industry Drivers:-

Drivers

As genomics-focused pharmacology continues to play a greater role in the treatment of various chronic diseases especially cancer,next-generation sequencing(NGS) is evolving as a powerful tool for providing a deeper and more precise insight at molecular underpinnings of individual tumours and specific receptors.

NGS offers advantages in accuracy, sensitivity and speed compared to traditional methods that have the potential to make a significant impact on the field of oncology. Because NGS can assess multiple genes in a single assay, the need to order multiple tests to identify the causative mutation is eliminated.

As genomics-focused pharmacology continues to play a greater role in the treatment of various chronic diseases especially cancer, next-generation sequencing (NGS) is evolving as a powerful tool for providing a deeper and more precise insight at molecular underpinnings of individual tumours and specific receptors.

NGS offers advantages in accuracy, sensitivity and speed compared to traditional methods that have the potential to make a significant impact on the field of oncology. Because NGS can assess multiple genes in a single assay, the need to order multiple tests to identify the causative mutation is eliminated.

Points Covered in Table of Content of Global Whole Exome Sequencing Market:

Chapter 1: Report Overview

Chapter 2: Global Market Growth Trends

Chapter 3: Value Chain of Whole Exome Sequencing Market

Chapter 4: Players Profiles

Chapter 5: Global Whole Exome Sequencing Market Analysis by Regions

Chapter 6: North America Whole Exome Sequencing Market Analysis by Countries

Chapter 7: Europe Whole Exome Sequencing Market Analysis by Countries

Chapter 8: Asia-Pacific Whole Exome Sequencing Market Analysis by Countries

Chapter 9: Middle East and Africa Whole Exome Sequencing Market Analysis by Countries

Chapter 10: South America Whole Exome Sequencing Market Analysis by Countries

Chapter 11: Global Whole Exome Sequencing Market Segment by Types

Chapter 12: Global Whole Exome Sequencing Market Segment by Applications

Check Complete Table of Contents @ https://www.databridgemarketresearch.com/toc/?dbmr=global-whole-exome-sequencing-market

Key Coverage in the Whole Exome Sequencing Market Report

Detailed analysis of Global Whole Exome Sequencing Market by a thorough assessment of the technology, product type, application, and other key segments of the report

Qualitative and quantitative analysis of the market along with CAGR calculation for the forecast period

Investigative study of the market dynamics including drivers, opportunities, restraints, and limitations that can influence the market growth

Comprehensive analysis of the regions of the Whole Exome Sequencing industry and their futuristic growth outlook

Competitive landscape benchmarking with key coverage of company profiles, product portfolio, and business expansion strategies

Browse Trending Reports:

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact Us: -

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:- corporatesales@databridgemarketresearch.com

Visit link:
Whole Exome Sequencing Market Projected to Reach CAGR of 19.0% Forecast by 2029, Global Trends, Size, Share, Growth, Future Scope and Key Player...

Posted in Molecular Genetics | Comments Off on Whole Exome Sequencing Market Projected to Reach CAGR of 19.0% Forecast by 2029, Global Trends, Size, Share, Growth, Future Scope and Key Player…

ALS Thought Leaders Weigh in Ahead of Second Amylyx Adcomm – BioSpace

Posted: September 8, 2022 at 2:07 am

From left:Amylyx Co-founders and Co-CEOs Justin Klee and Josh Cohen/Courtesy Amylyx

Wednesday offers a rare opportunity for Amylyx Pharmaceuticals, which will go before the FDAs Peripheral and Central Nervous System Drugs Advisory Committee in a second attempt to win recommendation for its amyotrophic lateral sclerosis (ALS) drug, AMX0035.

The FDA provided briefing documents Friday, and despite the unusual second adcomm, it does not appear to be convinced. To be approved, AMX0035 must meet substantial evidence of effectiveness, which may be derived by either a single very persuasive trial or a single adequate and well-controlled study plus confirmatory evidence, the documents state.

In March, the PCNSDAC voted 6-4 that the Phase II CENTAUR trial was not sufficient to prove efficacy in ALS. This trial, made up of 137 participants, showed a median overall survival (mOS) rate of 4.8 months compared to placebo.

Amylyx subsequently submitted additional analyses of the survival data from this trial and an open-label extension study. The agency considered this new data a major amendment and extended the drugs review time by three months. Recognizing the substantial unmet medical need in ALS, it again convened the PCNSDAC and here we are.

Wednesday's vote carries a higher burden for Amylyx to prove - that the data supporting AMX0035 is sufficient to "support approval".

The Case

Amylyx will present new analysis using the Rank Preserving Structural Failure Time Model (RPSFTM) to adjust for the effect of treatment crossover. This refers to patients who swtiched from treatment to placebo following the Phase II trial. In this analysis, the mOS in the intent-to-treat (ITT) population is 9.7 months.

The company also submitted analyses using natural history as a control to estimate survival time, as well as biomarker evidence from the Phase II PEGASUS trial of AMX0035 in Alzheimers disease (AD).

While Amylyx is presenting the above as confirmatory evidence, the FDA wrote, The presented RPSFTM analysis is not independent data and is simply a new method for analyzing the same survival data presented in the original NDA submission."

Of the biomarker analysis, the regulator said, The submitted biomarker data are not clear evidence of a CNS effect or a potential clinical benefit in patients with ALS.

AMX0035 is currently being assessed in a Phase III trial and the FDA expressed an inclination to wait until its completion, which is expected late next year or in early 2024. The PHOENIX trial will enroll approximately 600 individuals across the United States and Europe.

This places the Agency in a challenging situation of potentially making a regulatory decision that may not be subsequently aligned with the results of the ongoing study, the FDA stated.

For its part, Amylyx released the following statement Friday: AMX0035 is the first drug candidate to show benefit on function and survival in ALS in a randomized, placebo-controlled clinical trial, as a standalone therapy or when added to existing approved treatments.

Thought Leaders Weigh In

In ALS, which carries a typical death sentence of 3-5 years after diagnosis, any survival increase is enticing, particularly in a space that has seen little progress in recent years. BioSpace reached out to ALS thought leaders and drug developers prior to the adcomm for their perspectives.

Based on the data presented from their phase II trial, the Amylyx drug appears to offer a benefit in terms of slowing of disease progression and a possible survival benefit, said Stan E. Abel, CEO of ProJenX Inc., in an email.

ProJenX is in Phase I development with Prosetin, a mitogen-activated protein kinase (MAP4K) inhibitor targeting endoplasmic reticulum (ER) stress, a common feature in sporadic and familiar forms of ALS.

Given the benign safety profile, it is encouraging to see the FDA take a careful look at all the data, Abel continued. This was an area of consensus between Amylyx and the FDA in March, with both concluding AMX0035 did not pose a safety risk to patients.

There is another potential wrinkle in the case of AMX0035. In June, Amylyx notched its first regulatory approval when Health Canada approved the drug, now known as Albrioza, conditional on the results of the PHOENIX trial.

If AMX0035 does not receive approval in the U.S. or other countries, Abel noted it would add uncertainty and confusion to an already challenging clinical trial environment. He added that people living with ALS would likely seek treatment across borders which adds a significant burden to managing their care and [would put] more strain on the drug importation phenomenon.

Dr. Merit Cudkowicz, director of the Sean M. Healey & AMG Center for ALS and chief of neurology at Massachusetts General Hospital, shared her thoughts in an email.

A positive phase II study like Centaur where there is slowing of loss of function, prolongation of life - a survival benefit - and no safety issues is something we need to be able to get to our patients in the U.S., Cudkowicz said.

With recent breakthroughs in the space, there is a sense of momentum right now. If AMX0035 is ultimately approved, it will provide much needed positive news in the space and encourage further investment in other new promising therapies, Abel said.

Regulatory Flexibility for ALS

The ALS community has been calling for regulatory flexibility since the FDA approved Biogen's Aduhelmfor Alzheimers in June 2021.

Of the Sept. 7 adcomm, Stacy Lindborg, Ph.D., EVP and chief development officer at BrainStorm Cell Therapeutics said, We hope that a positiverecommendation would encourage the FDA to exercise regulatory flexibility.

BrainStorm is in the final stages of completing a BLA for NurOwn, an ALS candidate made up of autologous mesenchymal stem cells (MSCs) and neurotrophic factors (NTFs). Lindborg noted that the totality of evidence for NurOwn [brings] to light valuable insights on the nature of ALS research and biomarkers as predictors of clinical response.

In June, the FDA unveiled its Action Plan for Rare Neurodegenerative Diseases including ALS.The five-year strategy intends to improve and extend the lives of people living with rare neurodegenerative diseases by advancing the development of safe and effective medical products and facilitating patient access to novel treatments.

Cudkowicz made a comparison to the FDAs approval process for drugs in serious cancer indications.

The oncology branch of FDA approves drugs with smaller effects on survival based on a single study, and it would be a huge step forward in ALS if single studies like this could be approved conditional on future studies, she wrote in the same email.

Abel shared his thoughts on both the adcomm and the Action Plan.

The action plan for rare neurodegenerative diseases and this second Amylyx adcomm are both important steps that signal the FDAs willingness to apply thoughtful regulatory standards which take disease-specific considerations into account," he said.

Lindborg concurred, stating, FDAs release of the plan is an important step in adopting an outlook that prioritizes action to move potential therapies forward.

SVB Senior Research Analyst Marc Goodman provided a summary of his most recent note on Amylyx.

Significant unmet need in ALS with only two existing SOC (standard of care) agents that dont work very well should drive expedited regulatory approvals of AMX0035 and strong uptake, in combination with SOC agents," he wrote.

If AMX0035 does receive FDA approval, Cudkowicz said, It would strongly encourage more trials of other therapeutic approaches in ALS and would be a huge positive for the field. A negative opinion, she said, would be hugely disappointing for people living with ALS today and for ALS clinicians. It could risk putting the field back with less interest from industry.

BioSpace will have continued coverage of the Amylyx adcomm this week.

See the article here:
ALS Thought Leaders Weigh in Ahead of Second Amylyx Adcomm - BioSpace

Posted in Massachusetts Stem Cells | Comments Off on ALS Thought Leaders Weigh in Ahead of Second Amylyx Adcomm – BioSpace

Using HRT (Hormone Replacement Therapy) – breast cancer

Posted: September 8, 2022 at 2:06 am

Hormone replacement therapy (HRT) also called estrogen replacement therapy, menopausal hormone therapy, or post-menopausal hormone therapy can be an effective treatment for menopausal symptoms, but its important to know that some types of HRT can increase your risk of breast cancer.

HRT also can increase your risk of the cancer coming back (recurrence) if youve been diagnosed with breast cancer in the past. Because of this risk, doctors usually recommend that women with a history of breast cancer should not take types of HRT that affect the entire body (called systemic HRT).

HRT has also been linked to cardiovascular risks, such as heart disease, stroke, and blood clots.

However, all of these risks vary and depend on many factors, including:

type of HRT

the dose you take

your age when you start taking it

how long you use it

Years ago, before the link between HRT use and breast cancer risk was known, many women took HRT for years to ease menopausal symptoms and prevent bone loss. After 2002, when research linked HRT and breast cancer risk, the number of women taking HRT dropped dramatically.

Newer research that has followed women for a longer amount of time suggests the link between HRT and breast cancer risk is more complex than first thought, and using HRT remains a controversial topic.

Medical guidelines say the benefits of HRT such as quality of life and protection of bone health can outweigh the risks for certain women, particularly those who enter menopause at an early age. Because the risks and benefits are different for every woman, its best to educate yourself and talk with your doctor to decide if HRT is right for you.

HRT medicines usually contain the hormones estrogen, progesterone, or both, to replace the hormones a womans body stops making after menopause.

HRT is different than hormonal therapy medicines that block estrogen to treat hormone receptor-positive breast cancer.

There are two main types of HRT:

estrogen-only HRT

combination HRT, which contains both estrogenand progesterone (usually a synthetic form called progestin or progestogen)

Estrogen-only HRT usually is taken only by women who have had a hysterectomy (surgery to remove the uterus).

Combination HRT usually is taken by women who still have their uterus. Estrogen-only HRT can cause the lining of the uterus to become too thick a condition called estrogen-associated endometrial hyperplasia. This can increase the risk of cancer of the uterus, called endometrial or uterine cancer. The progesterone in combination HRT helps to prevent thiscondition.

In combination HRT, both hormones can either be combined into one medicine or given as separate medicines. The same dose of estrogen and progesterone can be taken daily (continuous HRT), or in different amounts on different schedules (sequential or cyclical HRT).

There are several ways to take or use HRT:

Systemic HRT usually contains a higher dose of estrogen and comes in many forms, including pills, skin patches, creams, gels, sprays or vaginal rings. Systemic means the medicines travel through the bloodstream to all parts of the body.

Topical (local) HRT contains a lower-dose of estrogen and comes in the form of creams, tablets, or rings applied or inserted into the vaginal area. These medicines arent as readily absorbed into your bloodstream and mostly stay in the vaginal tissue.

Systemic HRT effectively treats many symptoms of menopause, including hot flashes and night sweats. Topical HRT only works on vaginal symptoms, such as dryness and discomfort during sex.

Breast cancer risk differs depending on the type of HRT and a womans personal history of breast cancer.

Systemic combination HRT and breast cancer risk in women with no history of breast cancer

Based on results from the very large Womens HealthInitiative studies, combination HRT increases breast cancer risk and this increase in risk lasted for more than 10 years after the women stopped taking HRT.

Higher-dose combination HRT increases breast cancer risk more than lower-dose combination HRT.

Combination HRT also increases the likelihood that the cancer may be found at a more advanced stage. Combination HRT is linked to increased breast density, which can make it harder for mammograms to detect breast cancer.

Breast cancer risk appears to be higher with daily progesterone (continuous combination HRT) than with less frequent progesterone (sequential or cyclical combination HRT).

This increase in risk applies to bioidentical and natural hormone products as well as synthetic hormones. Bioidentical means the hormones in the product are identical to the hormones your body produces. Bioidentical hormones are derived from plants, so theyre sometimes called natural. Synthetic hormones are made in a lab and are also chemically identical to thehormones in your body. It's important to know that many herbal and bioidentical HRT products fall outside the jurisdiction of the United States Food and Drug Administration and so aren't subject to the same regulations and testing that medicines are.

Systemic estrogen-only HRT and breast cancer risk in women with no history of breast cancer

The American Cancer Society says estrogen-only HRT is not linked to a higher risk of breast cancer. The Womens Health Initiative studies also found no increase in breast cancer risk in women using systemic estrogen-only HRT.

But its very important to know that in women who have a uterus, using systemic estrogen-only HRT has been shown to increase the risk of endometrial cancer. Other studies have found a link between systemic estrogen-only HRT and a higher risk of ovarian cancer.

Its also important to know that research is conflicting when it comes to breast cancer risk and estrogen-only HRT. Some studies show a small increase in risk, and some dont.

Any type of systemic HRT and breast cancer risk in women with a history of breast cancer

Because doctors are concerned that systemic HRT can cause hormone receptor-positive breast cancer to come back, only a few studies have been done on HRT use in women with a history of breast cancer. A 2021 analysis of four studies found that women who took systemic HRT had a 46% higher risk of recurrence than women who didnt take HRT. Current recommendations say that women with a history of breast cancer should not take any type ofsystemic HRT.

Topical HRT and breast cancer risk in women with no history of breast cancer

Research suggests that topical HRT, such as low-dose vaginal estrogen creams, tablets, and rings do not increase breast cancer risk because most of the hormones stay in the vaginal tissue.

Topical HRT and breast cancer risk in women with a history of breast cancer

In 2016, the American Congress of Obstetricians and Gynecologists concluded that women whove been diagnosed with breast cancer who are having troubling systems such as pain during sex may consider using vaginal estrogen at the lowest effective dose if non-hormonal moisturizers or lubricants dont work.

Menopausal side effects can reduce quality of life for some women. You have to weigh the benefits of HRT against the risks.

If you're having severe hot flashes or other menopausal side effects and are considering HRT, talk to your doctor about all of your options. Ask how you can relieve your symptoms while minimizing your breast cancer risk. Some questions you may want to ask:

What is my personal risk of breast, ovarian, endometrial, and other types of cancer? How will this risk be affected by HRT?

What is my personal risk of other conditions that HRT can affect, such as heart disease and stroke?

What other options are there including non-hormonal medicines and complementary therapies to treat menopausal symptoms and osteoporosis?

Would topical HRT be a good option for me?

Learn more about Treating Menopausal Symptoms.

Poggio, F., Del Mastro, L., Bruzzone, M. et al. Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis. Breast Cancer Res Treat (2021). https://doi.org/10.1007/s10549-021-06436-9

Excerpt from:
Using HRT (Hormone Replacement Therapy) - breast cancer

Posted in Hormone Replacement Therapy | Comments Off on Using HRT (Hormone Replacement Therapy) – breast cancer

Bioidentical Hormone Replacement Therapy for Men

Posted: September 8, 2022 at 2:06 am

There are many benefits to bioidentical hormone replacement therapy (BHRT) for men. Find out if your hormones are balanced and learn how Biotes Method of hormone replacement therapy for men may help.

For decades, hormone therapy for men has been a common practice to address the symptoms of aging. Male bioidentical hormone replacement therapy (BHRT) may help men feel like themselves again. It may also help men who have always suffered from unbalanced hormones feel better for the first time. Male hormone replacement may also lower the severity of ailments not directly associated with reproductive symptoms. Biote has helped many patients with our unique approach to hormone therapy for men using pellet hormone therapy.*

Bioidentical hormones are identical to those present in the human body, and closely resemble the molecular structure of human hormones.

Hormone therapy for men can take the form of patches, creams, pills, injections, or pellets, all containing testosterone. The Biote Method of bioidentical hormone replacement for men uses pellets containing bioidentical testosterone and may help with many different symptoms commonly associated with hormonal imbalance.*

Bioidentical hormone replacement for men may help any man whose hormones are out of balance. Hormone imbalance frequently occurs as we age. However, there are instances like hypogonadism that can occur at any age. Biote Certified Providers will qualify patients based on their individual lab results and current hormone levels.*

Pellets used for male BHRT are high-quality and custom-compounded with bioidentical testosterone. In an in-office appointment, these pellets are inserted subcutaneously in a patients upper buttocks. Within up to two to four weeks after a pellet insertion, the hormone therapy for men may begin to alleviate some unwanted symptoms. However, everyones body is different and some patients report feeling the full benefits after the second insertion.*

Read more here:
Bioidentical Hormone Replacement Therapy for Men

Posted in Hormone Replacement Therapy | Comments Off on Bioidentical Hormone Replacement Therapy for Men

Hormone Replacement Therapy for Over 60s | Gransnet

Posted: September 8, 2022 at 2:06 am

For some women going through menopause, hormone replacement therapy (HRT) can be a godsend, but some GPs are hesitant to prescribe it to women over 60, even though they may still be suffering from menopause symptoms. If you're struggling to decide whether it's right for you,here's our guide to starting HRT at 60, including the benefits, risks and, if you decide against it, effective alternatives that you can try.

Get advice and support on our menopause forum...

HRT is a common abbreviation for hormone replacement therapy.In short, it is a man-made replacement for the hormones your body stops producing once you hit menopause (progesterone and oestrogen). Taking HRT helps to restore these hormone levels and, as a result, can help to relieve menopausal symptoms, particularly the hot flushes that so many women struggle with.

Common symptoms of menopause include:

Some of these symptoms may have begun while you were still having periods such as during the perimenopause. You might find that you experience different symptoms with each stage of the menopause and with differents degrees of severity. Evidence has suggested that there are a few things that can help ease the severity of those that you do experience, such as altering your diet and exercising regularly. Sometimes, however, it's not as easy as that, and when these measures fail, you may want to consider hormone replacement therapy.

Hormone replacement therapy comes in various forms, including tablets, patches, gels and creams. The effects of HRT vary from woman to woman - what is right for you will depend on the symptoms you are experiencing and should be discussed with your doctor.

HRT tablets are the most common form, with HRT patches following a close second. Both of these options are available in oestrogen-only and combined (oestrogen and progesterone) forms, and the patches are replaced every few days, while the tablets are taken every day.

Oestrogen is also available as a gel which is applied daily to the skin. Oestrogen pessaries that are placed in the vagina can help reduce local dryness, but do not tackle more general symptoms. Here's an overview of the different types of hormone replacement therapy, including the benefits, risks and side effects of each:

While HRT can be beneficial to menopausal women, there are risks with each type of medication. If you're considering it, speak to your GP who will advise you on the best type for you.

Most women hit menopause between the ages of 45 and 55 with the average age being 51. However, symptoms can last up to 12 years after you reach menopause. It's also worth keeping in mind that not everyone opts for hormone replacement therapy and it may not be suitable for some, including those with a history of breast and ovarian cancer in the family.

If you find that your GP won't prescribe it to you, but you feel you would like a second opinion on the potential benefits of HRT after 60, it could be worth going to a doctor who specialises in the menopause.

Join over 250,000 userson Gransnet today

"I am aware of the risk factors, but I value my current quality of life. If day-to-day living is intolerable, then for me the risks are worth it."

As with most medication, HRT carries its own risks and side effects, both short-term and long-term. After a study in 2002 found that it was linked to increased risk of breast cancer, the number of women taking the drug plummeted. NICE (The National Institute for Health and Care Excellence)guidelines released in 2015, however, suggested that better information about the risks and benefits of HRT over 60 could help many of the women, who have ruled out taking the drug for fear of the risks, come to a more balanced decision about treatment.The NHS advises that generally the benefits of taking hormone replacement therapy outweigh the risks.

A study by University of Nottingham researchers found that a small number of people taking certain types of HRT tabletscould be more at risk from blood clots. While the overall risk is low, the study concluded thatHRT gels and patches were the safest to use.

A recent study suggested that there was a small increased risk of developingAlzheimer's disease with long-term use of HRT, particularly for those who use HRT for over 10 years. However, medical professionals have stated that women shouldn't be too concerned about the results of the study, as the risk is small and it was an observational study not accounting for other factors.

In cases where a woman is taking combined HRT (as opposed to oestrogen-only HRT, which carries a smaller risk), her chances of developing breast cancer are doubled. However, statistics also show that breast cancer risks return to normal within five years of coming off the medication.

There is no evidence that bio-identical hormones are any safer than standard HRT. We spoke to Dr. Marilyn Glenville PhD, the UK's leading nutritionist specialising in women's health:

"Research suggests that it is not appropriate for women over the age of 60 to start HRT because the risks are higher. Bio-identical hormones are chemically similar in structure to the hormones your body would produce naturally, but they carry the same risks as conventional HRT and they are not licensed by the UK regulatory authorities. The bio-identical hormones are still made in a lab in the same way that the conventional medication would be made and from the same sources. The big question is when would you stop taking them? If it is correct to replace those naturally declining hormones then you would need to take them forever."

These risks are best discussed with your doctor, who can help you make an informed decision. You can find more, specifically regarding cancer risks, on the Cancer Research website.

The benefits of HRT are generally thought to outweigh the risks in women under 60, or when used within 10 years of the beginning of menopause. But what about after 60?

As women reach this age, it's fairly common for GPs to start suggesting they stop or gradually reduce their dosage. Gransnetters themselves mostly recommend reducing the dosage slowly to minimise the possible negative effects of symptoms making themselves known again.

"I am convinced that very gradually coming off HRT was the way to do it. The whole process took over a year but, apart from some hot flushes for the first six months, I am now more or less symptom-free."

If your GP has advised against taking HRT or you don't want to run the associated risks, there are many alternative therapies to consider.

Make sure you get regular exercise, including strength training, cardio or even yoga, Pilates or tai chi.

You can do this with food.Chickpeas, beans, soya milk and soya beans all contain phytoestrogens which work to raise levels that have taken a dive due to menopause.

This medicinal plant has long been hailed as helpful in reducing night sweats and hot flushes. However, it's important to note here that no studies have proven that it is either safe or effective. That said, anecdotal evidence seems to suggest that it helps with temperature regulation in some women. It can cause stomach upsets though and, in rare cases, can affect the liver so do seek your doctor's advice before taking it.

This supplement is proven to help with mood regulation, so could potentially be very helpful for those who suffer from depression during menopause. Do talk to your doctor before taking it though, as it is known to interfere with certain medications.

There is evidence that antidepressants, which alter serotonin levels in the brain, can also help with body temperature regulation. They can help to ease hot flushes and sweats, and can be also help to ease the mood changes that some women experience at the time of the change.

The LadyCare magnet is a device that claims to ease menopause symptoms naturally. According to its creators, it is effective for 71% of women who try it and claims to be particularly helpful in alleviating hot flushes, mood changes and sleeping problems. It claims to work by rebalancing the Automatic Nervous System (ANS) and is worn inside your underwear.

"It could be a placebo effect, but the LadyCare magnet works for me. Anything's worth a try when you have those tropical moments!"

"My GP tells me he has patients in their 80s who are still on HRT and, as long as they are happy and healthy and have regular checks, he is happy for them to continue. Needless to say, I am back on a very low dose and feeling great."

"I am 68 and suffer very badly with hot flushes. I had patches for many years, but the doctors are reluctant to prescribe them to me now."

"I would rather take it and face minimal risks (with no personal or family histories) than suffer the awful symptoms which were ruining all aspects of my life."

"HRT gave me my life and my marriage back."

"The worst thing about coming off HRT is that it has totally messed up my sex life! I've become dry in a certain area and trying to sort that problem out is no fun. I am seriously thinking of going back on it if my doctor will prescribe it again. I know the risks, but I love my husband more."

"I was on HRT for 10 years and stopped when I had major surgery. The only symptom that came back were the flushes but they were much less intense and mostly daytime ones, which I dealt with fine."

"After 10 years, my doctor suggested it was time to stop taking it. No weaning off. But I don't recall there being any particular side effects to giving it up."

"I made the decision not to take HRT, but what helped with hot flushes for me was a large glass of soya milk every day."

"Hot flushes all night long. Try all the natural things to ease your symptoms."

"I think that one of the big difficulties with these decisions is that GPs and others seem to be clearly in one camp or another. My previous doctor was not prepared to prescribe it to me, whereas my current GP doesn't see why I might have any reason to worry."

Disclaimer: The information on our health pages is only intended as an informal guide and should not be treated as a substitute for medical advice. Gransnet would urge you to consult your GP before you begin any form of treatment if you're concerned about your weight, have existing health conditions and/or are taking medication.

Continued here:
Hormone Replacement Therapy for Over 60s | Gransnet

Posted in Hormone Replacement Therapy | Comments Off on Hormone Replacement Therapy for Over 60s | Gransnet

Rethinking "The Change": Discover 40+ Ways to Embrace Menopause – PR Newswire

Posted: September 8, 2022 at 2:06 am

DrTalks.comhas partnered with Dr. Sharon Stills and 40+ experts to unlock the secrets of a sexy menopause at a 7-day virtual summit.

CARLSBAD, Calif., Sept. 7, 2022 /PRNewswire/ -- Join DrTalks.com with the creator of RED Hot Sexy Meno(pause), Dr. Sharon Stills, from Tuesday, September 20th through Tuesday, September 27th to learn how to have a sexy, happy, low-stress menopause. Featured guests include Dr. Keesha Ewers (Best-Selling author and Integrative Medicine expert), Dr. Anna Cabeca (Triple Board-Certified OBGYN and Author), and Dr. Heather Sandison, ND (Founder of Marama). Each expert will be interviewed directly by Dr. Sharon Stills.

We talk about menopause in whispers - if we talk about it at all. We fear hot flashes, fatigue, mood swings, libido changes, and potential weight gain. But we do little if anything to prep our bodies for this massive change. But here's the good news. Menopause is more than "the change." It's an opportunity to pivot. And it CAN be a beautiful, powerful, transformative time if you lean into the transition and reach for the kind of medicine that doesn't come in a bottle.

Rethinking The Change: Discover 40+ Ways to Embrace Menopause

The Mastering the Meno(pause) Transition Summit brings together more than 40 guest speakers, including doctors, OBGYNs, functional medicine practitioners, naturopaths, nutritionists, and more, to teach you how to have a red hot, sexy menopause. Topics will include prepping your body for menopause during perimenopause, how to manage the symptoms of menopause, what habits make symptoms worse, what menopause can teach you about your sexuality, how to get the best sleep of your life, how to boost libido, more. Attendees will discover 40+ ways to embrace menopause as a time of transition and will leave the summit feeling empowered to craft the second half of their story with intention.

This summit is for anyone currently experiencing menopause or perimenopause and who wants to be fully prepared for this incredible time of change. Register for the Mastering the Menoo(pause) Transition Summit and prepare for a sexy, vibrant menopause!

About Dr. Sharon Stills: Dr. Sharon Stills is a Naturopathic Medical Doctor who helps perimenopausal and menopausal women to pause and evaluate life so they can live the second act of their story stronger, healthier, and sexier while aging backward. She has more than 20 years of medical experience and an extensive background in anti-aging, bioidentical hormone replacement therapy, and European biological medicine. She is the founder of the RED Hot Sexy Meno(pause) Program and the host of The Science of Self Healing podcast.

Media ContactChristi Simoneaux[emailprotected]

SOURCE DrTalks

Excerpt from:
Rethinking "The Change": Discover 40+ Ways to Embrace Menopause - PR Newswire

Posted in Hormone Replacement Therapy | Comments Off on Rethinking "The Change": Discover 40+ Ways to Embrace Menopause – PR Newswire

Seven days in medicine: 31 Aug to 6 Sep 2022 – The BMJ

Posted: September 8, 2022 at 2:06 am

Moderna sues Pfizer over vaccine technology

The vaccine manufacturer Moderna is suing the US drug company Pfizer and its German partner, BioNTech, for patent infringement of mRNA technology used in the first covid-19 vaccines, which it says it developed before the pandemic. Moderna alleges in a lawsuit filed in the US and Germany that the companies copied two key elements of its intellectual property. The first is a chemical modification whereby a vaccine avoids provoking an undesirable immune response, and the second relates to the way both of the covid vaccines target the spike protein. Early in the pandemic Moderna said that it would not enforce patents of its covid vaccine, to help other drug companies develop their own vaccines.1

The head of the UK governments taskforce on hormone replacement therapy (HRT) has returned to her role overseeing the vaccine taskforce, ahead of the rollout of the omicron booster programme this month. Madelaine McTernan was asked to take on the HRT role in April to tackle serious supply issues. Four months later the access to HRT products has improved, but shortage protocolswhich limit dispensing to three months supply and allow specified alternative products to be supplied if necessarywill remain in place for 12 HRT products, including some gels and

Read more:
Seven days in medicine: 31 Aug to 6 Sep 2022 - The BMJ

Posted in Hormone Replacement Therapy | Comments Off on Seven days in medicine: 31 Aug to 6 Sep 2022 – The BMJ

If Covid Distorted Your Sense Of Time, Don’t Panic: You’re In The Majority – Kaiser Health News

Posted: September 8, 2022 at 2:06 am

A new study says a majority of Americans experienced a muddled sense of time during covid, with trauma from the pandemic experience to blame. Medical misinformation, future pandemic modeling, protection from previous covid infections, and more are also in the news.

The Washington Post:Pandemic Trauma Caused Many To Lose Their Sense Of TimeDid you lose track of time during the early days of the pandemic? If so, youre not alone. A new study says a majority of Americans experienced time distortions at the beginning of the pandemic, which are common during traumatic times. (Blakemore, 9/5)

More on the pandemic's effects

Chicago Tribune:University Of Chicago Offers Class On Medical MisinformationPatients have long been told to turn to their doctors for accurate, trusted health information. But in recent years, especially during the COVID-19 pandemic, doctors voices have sometimes been drowned out by social media users who blast misinformation across the globe, leading patients to make questionable, and sometimes dangerous, choices about their health. (Schencker, 9/6)

Wyoming Public Radio:University Of Wyoming Researchers Will Help Formulate Post-Pandemic Modeling For Future PandemicsThe University of Wyoming was recently selected as one of just a few research institutions nationwide to receive approximately one million dollars in grant funding for research into pandemic modeling. (Cook, 9/2)

The CT Mirror:CT Hospital Housekeepers Push For Essential Worker Relief, BenefitsDuring the terrifying spring of 2020, as COVID-19 paralyzed the nation and hospitals buckled, Katherine Stearns was on the front lines in Windham Hospitals emergency room. Stearns works as the lead housekeeper at the hospital. (Golvala, 9/4)

KHN:He Stood His Ground: California State Senator Will Leave Office As Champion Of Tough Vaccine LawsA California lawmaker who rose to national prominence by muscling through some of the countrys strongest vaccination laws is leaving the state legislature later this year after a momentous tenure that made him a top target of the boisterous and burgeoning movement against vaccination mandates. State Sen. Richard Pan, a bespectacled and unassuming pediatrician who continued treating low-income children during his 12 years in the state Senate and Assembly, has been physically assaulted and verbally attacked for working to tighten childhood vaccine requirements even as Time magazine hailed him as a hero. Threats against him intensified in 2019, becoming so violent that he needed a restraining order and personal security detail. (Hart, 9/6)

In updates on the spread of covid

CIDRAP:Study: Previous COVID-19 Infection Offers Protection Against BA.5Infections with previous COVID-19 variants offer more protection against the Omicron BA.5 subvariant in vaccinated people compared with vaccinated people who had no previous infections, according to a New England Journal of Medicine study yesterday. (9/1)

CIDRAP:Low Testosterone In Men May Raise Risk Of COVID HospitalizationMen with low testosterone levels and COVID-19 were more than twice as likely as men with normal concentrations to be hospitalized, but those treated with hormone replacement therapy weren't at elevated risk, suggests an observational study today in JAMA Network Open. (Van Beusekom, 9/2)

USA Today:CDC Report: 44% Of People Hospitalized With COVID Got Third Dose, BoosterNearly half of Americans hospitalized in the spring for COVID-19 were fully vaccinated and got a third dose or booster, according to a report by the CDC. (Rodriguez, 9/2)

Also

San Francisco Chronicle:UC Berkeley To Require, But Not Enforce, Indoor Masks For Students Who Decline Flu VaccineUC Berkeley will again require students and employees who choose not to get vaccinated against influenza to mask up indoors during the upcoming flu season, a rule that has been in place since 2020 but led to outcry last week from critics of vaccines, masks and mandates relating to either. (Asimov, 9/3)

Read the original:
If Covid Distorted Your Sense Of Time, Don't Panic: You're In The Majority - Kaiser Health News

Posted in Hormone Replacement Therapy | Comments Off on If Covid Distorted Your Sense Of Time, Don’t Panic: You’re In The Majority – Kaiser Health News

SEngine Precision Medicine Partners with Vincere Cancer Center to Increase Access for First Responders to Get Personalized Cancer Treatments via the…

Posted: September 8, 2022 at 2:03 am

SEATTLE, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Seattle-based Precision Oncology company SEngine Precision Medicine and Vincere Cancer Center in Scottsdale, Arizona are collaborating to provide more cancer patients with access to SEngine’s signature diagnostic test, the PARIS® Test.

Read more here:
SEngine Precision Medicine Partners with Vincere Cancer Center to Increase Access for First Responders to Get Personalized Cancer Treatments via the...

Posted in Global News Feed | Comments Off on SEngine Precision Medicine Partners with Vincere Cancer Center to Increase Access for First Responders to Get Personalized Cancer Treatments via the…

Page 239«..1020..238239240241..250260..»